BioCheck

What BioCheck does

BioCheck is a private in vitro diagnostics company founded in April 1997 and headquartered in Pleasant Hill, California, that develops, manufactures, and distributes immunodiagnostic instruments, ELISA kits, and antibodies for clinical and research markets worldwide. The company's product portfolio spans four proprietary instrument platforms—HYBRiD XL (high-throughput fully automated immunoassay and clinical chemistry analyzer), DS2 (low-throughput ELISA automation), DSX (medium-throughput ELISA automation with 3,400+ units deployed globally), and DxDATA (chemiluminescent immunoassay analyzer with 17-29 minute detection time)—alongside a catalog of 109+ ELISA kits and monoclonal, polyclonal, and recombinant antibodies covering cardiac, fertility, thyroid, tumor, hepatitis, food safety, TORCH, and H. pylori categories. Manufacturing operates under ISO 13485 certification and FDA 21 CFR Part 820 GMP compliance, with DxDATA test menu items holding CE IVD compliance for European distribution.

BioCheck monetizes through a hybrid model: capital equipment sales of instruments (requiring contact-based quoting for the HYBRiD XL, DS2, DSX, and DxDATA systems), one-time purchases of ELISA kits and antibodies through its biocheckinc.com e-commerce storefront, and OEM components licensing. Distribution is executed through six wholly-owned subsidiaries—DRG International (USA), DRG Instruments GmbH (Germany), DRG TechSystem and DRG BioMed (Russia), DRG MedTek (Poland), and DRG Diagnostics (Czech Republic)—with DRG International's distributor network reaching over 110 countries. The company serves four primary customer segments: clinical laboratories (routine diagnostic testing), research institutions (assay development and biomarker discovery), healthcare providers (point-of-care and decentralized diagnostics), and OEM partners (custom diagnostic components).

The August 2021 acquisition of DRG International was the defining strategic event, transforming BioCheck from a US-focused antibody supplier into a multi-continent IVD platform and adding the HYBRiD XL analyzer, European manufacturing, and 110-country distribution in a single transaction. Leadership is concentrated under CEO and Chairman Roy Paxton Yih, who brings 30+ years of prior experience leading Biocare Medical LLC. The company has 51-100 employees and no disclosed venture or private equity backing.

Name

BioCheck

Legal name

BioCheck Inc.

Website

https://biocheckinc.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

51–100 employees

Short description

BioCheck is a private in vitro diagnostics company that develops, manufactures, and distributes immunodiagnostic instruments (ELISA and chemiluminescent platforms), ELISA kits, and antibodies for clinical laboratories, research institutions, and healthcare systems across 110+ countries.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Clinical Chemistry & Immunoassay Systems (HLAHAAAA)

akta.pro secondary industries

Immunoassay Diagnostics (ELISA, chemiluminescence, serology) (HLAAALAB), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• In vitro diagnostics
• Immunoassay reagents
• ELISA kits
• Diagnostic instruments
• Antibody reagents

Headquarters

HQ city

Foster City

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Instruments: Sale of automated ELISA and CLIA analysis instruments including HYBRiD XL, DS2, DSX, and DxDATA systems. These are capital equipment purchases for laboratories and healthcare facilities.
2. Antibodies and Reagents: Sale of research and diagnostic-grade antibodies including monoclonal, polyclonal, and conjugated antibodies for various applications including cardiac markers, tumor markers, fertility, thyroid, and infectious disease testing.
3. ELISA Kits: Pre-configured ELISA kit products for clinical diagnostics and research applications.
4. OEM Products: Custom OEM diagnostic products and components for integration into third-party diagnostic systems.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

BioCheck develops, manufactures, and distributes in vitro immunodiagnostic products, including automated ELISA and chemiluminescent immunoassay (CLIA) instruments (HYBRiD XL, DS2, DSX, DxDATA), ELISA test kits, and a broad portfolio of monoclonal, polyclonal, and recombinant antibodies. These products are used by clinical laboratories, research institutions, and healthcare providers for diagnostic testing and biomedical research across multiple disease categories including cardiac markers, tumor markers, fertility, thyroid, hepatitis, infectious diseases, and traumatic brain injury.

Product overview

BioCheck offers a comprehensive portfolio of in vitro diagnostic products organized into three main categories: automated instruments (HYBRiD XL®, DS2®, DSX®, DxDATA™), ELISA kits, and antibodies. The instrument lineup progresses from low-throughput manual ELISA automation (DS2®) to medium-throughput systems (DSX®) to high-throughput fully automated immunoassay analyzers (HYBRiD XL®). The DxDATA™ system provides chemiluminescent immunoassay capability with TBI testing assays. All instruments are designed to work with DRG ELISA kits and reagents, creating an integrated diagnostic ecosystem supporting clinical laboratories, research institutions, and healthcare systems worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• HYBRiD XL A fully automated analyzer for Immunoassays and Clinical Chemistry, designed for high-volume diagnostic testing in clinical laboratory settings.
• DS2 Low throughput ELISA automation instrument with small footprint, barcode scanning, real-time error reporting, walk-away automation, and continuous sample loading for up to 100 samples with 2 plate incubators.
• DSX Medium throughput ELISA automation system with twice the capacity of DS2, featuring up to 96 samples on-board, 4-plate incubator, automated monitoring, and real-time alerts for gross-pipetting errors.
• DxDATA Automated Chemiluminescent Immunoassay analyzing system with 8-channel sample throughput, supporting serum, plasma, and whole blood samples with 17-29 minute detection time. Available assays include GFAP CLIA Kit and PGP9.5 CLIA Kit for Traumatic Brain Injury testing.
• ELISA Kits High-quality enzyme-linked immunosorbent assay kits for clinical diagnostics and research applications, designed for use with DRG Instruments automation systems including DS2 and DSX.
• Antibodies Comprehensive range of high-quality antibodies including monoclonal, polyclonal, and recombinant types across multiple categories: Cardiac Markers, Fertility, Thyroid, Tumor Markers, Hepatitis, Food Safety, TORCH IgG/IgM, Ferritin/HGH/IgE, and H. pylori.

Quantifiable outcome

• Improved patient outcomes through evidence-based diagnostic testing
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and regional.

• DRG InternationalcoreStrategic or Co-development Partner · 1 August 2021BioCheck acquired DRG International in August 2021, expanding its global footprint. DRG International is a leading manufacturer of clinical diagnostic and research ELISAs with distributors in over 110 countries, and is the manufacturer of the DRG:HYBRiD-XL automated analyzer. This acquisition established BioCheck's presence in the USA, Germany, Russia, Poland, and Czech Republic.
• DRG Instruments GmbHcoreStrategic or Co-development PartnerSubsidiary located in Marburg, Germany specializing in the development and production of innovative ELISAs and Chemiluminescent assays for routine and research applications in diabetes diagnosis, endocrinology, prenatal/neonatal supervision, and thyroid function.
• DRG TechSystemregionalChannel Partner/ Reseller/ DistributorSubsidiary in Moscow, Russia providing services for supply contracts for medical equipment, currency conversion, customs formalities, installation, adjustment, warranty and post-warranty service.
• DRG BioMedregionalChannel Partner/ Reseller/ DistributorSubsidiary in St. Petersburg, Russia equipping departments of anesthesiology and resuscitation, functional diagnostics, radiation diagnostics, and electrophysiological laboratories for surgical treatment of rhythm and conduction disorders.
• DRG MedTekregionalChannel Partner/ Reseller/ DistributorSubsidiary in Warsaw, Poland offering and distributing high-quality medical equipment and laboratory diagnostics products, with maintenance services for installation, repair and use of equipment.
• DRG DiagnosticsregionalChannel Partner/ Reseller/ DistributorSubsidiary in Brno, Czech Republic engaged in import and distribution of in vitro diagnostics for medical and research laboratories, including distribution of unique IVD products from DRG USA and Germany and diagnostics from other manufacturers.
• DRG Diagnostics GmbHcoreTechnology or IntegrationDRG Diagnostics GmbH provides TBI (Traumatic Brain Injury) assay products including GFAP CLIA Kit and PGP9.5 CLIA Kit for use with the DxDATA system.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Merck KGaA (MilliporeSigma): Global life science tools provider with extensive antibody, ELISA, and diagnostic reagent offerings. Comparable on the research-reagent and OEM reagent side of BioCheck's catalog.
• Revvity (formerly PerkinElmer): Life sciences and diagnostics company offering immunoassays, reagents, and analytical instruments. Comparable in instrument-plus-reagent business model and life science research customer overlap.
• Bio-Rad Laboratories: Established life science and clinical diagnostics company with broad immunoassay, ELISA, and life science reagent portfolios. Comparable on both the diagnostic kit and research antibody/reagent side.
• Bio-Techne: Developer of high-quality reagents, antibodies, and assay kits for research and clinical diagnostics. Direct overlap with BioCheck's antibody and ELISA kit product lines.
• DiaSorin: Global specialty IVD company focused on immunodiagnostics and chemiluminescence immunoassays. Highly comparable to BioCheck's CLIA-based DxDATA system and ELISA franchise.
• QuidelOrtho: Specialty diagnostics company with immunoassay and specialty testing products. Overlaps with BioCheck's clinical diagnostic franchise across multiple disease categories.

Direct peers

• Dynex Technologies: Manufacturer of the DS2 and DSX ELISA automation systems that BioCheck sells under its brand. Closest direct comparable on the instruments side of the business.
• Abcam (Danaher): Leading antibody and immunoassay reagent supplier, recently acquired by Danaher. Direct comparable to BioCheck's antibody catalog across cardiac, fertility, thyroid, and tumor marker categories.
• DRG International: A wholly-owned subsidiary of BioCheck (acquired 2021) but historically a direct peer, manufacturing clinical diagnostic and research ELISAs and the HYBRiD-XL analyzer. Highly comparable in product mix and customer base.

Emerging players

• Monoclonal Antibodies Inc. Specialty antibody and immunoassay reagent developer serving research and diagnostic markets. Niche competitor in the smaller-scale, specialty antibody space where BioCheck also operates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioCheck